ESMO Clinical Practice Guidelines: Haematological Malignancies
The ESMO Clinical Practice Guidelines (CPG) are intended to provide the user with a set of recommendations for the best standards of cancer care, based on the findings of evidence-based medicine.
Latest enhanced and revised set of guidelines
ESMO has Clinical Practice Guidelines on the following Haematological Malignancies: Philadelphia chromosome-negative chronic myeloproliferative neoplasms, Hairy cell leukaemia, Myeloproliferative neoplasms, Mantle cell lymphoma, Myelodysplastic syndromes, Waldenström's macroglobulinaemia, Multiple myeloma, Acute myeloblastic leukaemia in adult patients, Chronic lymphocytic leukemia, Chronic myeloid leukemia, Hodgkin's lymphoma, Diffuse large B-cell lymphoma, Gastric marginal zone lymphoma of MALT type, Primary cutaneous lymphoma, newly diagnosed and relapsed Follicular lymphoma, acute lymphoblastic leukaemia and extranodal diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma.
They include information on incidence, diagnosis, staging and risk assessment, treatment, response evaluation and follow-up.